Intermittent Preventive Treatment for Malaria in Infants (IPTi) is a new strategy which aims to combine the short-term protection of chemoprophylaxis with the long-term protection of naturally-acquired immunity to reduce morbidity from malaria infections during infancy. The Bill and Melinda Gates Foundation requested that the Institute of Medicine (IOM) conduct an independent assessment of the IPTi efficacy studies using sulfadoxine-pyrimethamine (IPTi-SP) that have been previously conducted by the IPTi Consortium. The IOM convened a committee to evaluate the evidence concerning IPTi-SP, which included addressing issues related to its utility and safety, as well as program management aspects of IPTi. The resulting letter report contains the findings, conclusions, and recommendations of the IOM committee. Overall, the committee found that the evidence presented makes IPTi-SP a promising public health strategy to diminish the morbidity from malaria infections, especially for the incidence of clinical malaria, among infants at high risk who reside in areas of high- or moderate-intensity transmission and is worthy of continued investment. The committee also cautioned that during large-scale implementation problems such as drug supply and logistics; monitoring and resistance; and community acceptance and reaction to IPTi-SP could arise. To maximize the greatest public health impact, the committee advised that these issues would best be addressed in an appropriate local context.
Table of Contents
|Appendix A Committee Members and Staff||65-65|
|Appendix B References||66-73|
|Appendix C Glossary||74-75|
|Appendix D Meeting Agenda||76-78|
|Appendix E Reviewers||79-79|
|Appendix F List of Tables, Figures, and Boxes||80-80|
The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:
Click here to obtain permission for the above reuses. If you have questions or comments concerning the Rightslink service, please contact:
Rightslink Customer Care
Tel (toll free): 877/622-5543
To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.
To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, please click here to view more information.